Dr. Wise is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
160 East 34th Street
10th Floor
New York, NY 10016Phone+1 212-731-6366Fax+1 212-731-5527- Is this information wrong?
Summary
- My expertise in the management of advanced urologic cancers incorporates the most recently developed imaging and therapeutic modalities and a broad array of targeted and immunotherapy-based clinical trials.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2013
- OtherClass of 2011
- Perelman School of Medicine at the University of PennsylvaniaClass of 2011
Certifications & Licensure
- NY State Medical License 2013 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2022 Jun 27
Roles: Contact
Publications & Presentations
PubMed
- High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy mon...Byun, D., Jonathan W Lischalk, Astrid Sanchez, Vianca F Santos, Christopher Mendez, Meredith Akerman, Todd Carpenter, Moses Tam, David Byun, David R Wise, Anand Mahade...> ;Radiation Oncology. 2024 Mar 4
- TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.Stacy Loeb, Scott W Keith, Heather H Cheng, Amy E Leader, Laura Gross, Tatiana Sanchez Nolasco, Nataliya Byrne, Rebecca Hartman, Lauren H Brown, Christopher Michael Pi...> ;JCO Precision Oncology. 2024 Mar 1
- A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Wise, D., Pachynski, R., Denmeade, S., Aggarwal, R., Deng, J., Febles, V., Balar, A., Economides, M., Loomis, C., Selvaraj, S., Haas, M., Kagey, M., Newman, W., Baum, ...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 10
- Join now to see all
Press Mentions
- EU Thumbs up for Oral ADT for Prostate CancerFebruary 28th, 2022
- Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 MutationsSeptember 24th, 2019
- European Urologists Release Position Paper on Immune Checkpoint Inhibitor ToxicitiesAugust 2nd, 2019
- Join now to see all
Hospital Affiliations
- NYU Langone HospitalsNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: